The recent RATIFY study (NCT00651261), which led to the approval of midostaurin for the treatment of FLT3-mutated AML patients, was made possible through the cooperation of many hospitals sharing patient data. Speaking from the European School of Hematology (ESH) International Conference on Acute Myeloid Leukaemia 2017 in Estoril, Portugal, Miguel Sanz, MD, of the University Hospital La Fe, Valencia, Spain, discusses why this collaboration is so vital to identifying new subtypes of and treatments for diseases.
The need for collaboration amongst hospitals: learning from RATIFY
